Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AIM ImmunoTech Q2 2024 GAAP EPS $(0.03) Beats $(0.12) Estimate

Author: Benzinga Newsdesk | August 16, 2024 07:25am
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.12) by 75 percent. The company reported quarterly sales of $50.00 thousand which beat the analyst consensus estimate of $11.67 thousand by 328.57 percent. This is a 19.05 percent increase over sales of $42.00 thousand the same period last year.

Posted In: AIM


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist